Wegovy Slashes the Risk of Heart Attack and Stroke in a Landmark Trial
The current trial was sponsored by Novo Nordisk, the maker of Wegovy and Ozempic, and tracked patients for two years at locations worldwide. Half of the participants received weekly injections of semaglutide while the other half received a placebo. Neither group knew which they were getting. More than three-quarters of the patients had previously experienced a heart attack, and close to a quarter had chronic heart failure. The average age of the volunteers was 61.6, and about three-quarters were men.In patients taking semaglutide, heart rate, blood pressure, cholesterol levels, and a biomarker of inflammation dropped by a larger degree than in those getting a placebo. But what the trial investigators were most interested in was whether semaglutide could reduce the risk of major cardiovasc...
